GNLX · Genelux Corporation

Summary

Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC on March 19, 2026, enabling the offer and sale of up to $100,000,000 of its common stock through at-the-market offerings. Net proceeds will fund general corporate purposes, including research and development, clinical trials, capital expenditures, and working capital.

Key takeaways

• Entered Sales Agreement with TD Securities (USA) LLC (TD Cowen) on March 19, 2026
• Aggregate offering price up to $100,000,000 of common stock, par value $0.001 per share
• TD Cowen to act as sales agent and/or principal with up to 3.0% commission on gross proceeds
• Sales pursuant to Form S-3 Registration Statement (File No. 333-276847, effective February 13, 2024)
• Company may suspend or terminate sales at any time
• Exhibits include Sales Agreement (1.1) and legal opinion (5.1)